Genmab A/S Capital Increase from Employee Warrant Exercise
Ticker: GNMSF · Form: 6-K · Filed: Sep 9, 2025 · CIK: 1434265
| Field | Detail |
|---|---|
| Company | Genmab A/S (GNMSF) |
| Form Type | 6-K |
| Filed Date | Sep 9, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: capital-increase, employee-stock-options, disclosure
Related Tickers: GMAB
TL;DR
Genmab raised ~1.1M DKK from employee stock options on Sept 9, 2025.
AI Summary
On September 9, 2025, Genmab A/S announced a capital increase of approximately DKK 1.1 million (USD 0.16 million) due to the exercise of employee stock options. This event is part of Genmab's ongoing employee incentive programs.
Why It Matters
This capital increase reflects employee engagement and confidence in the company's future, potentially impacting share count and dilution.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of a capital increase resulting from employee stock option exercises, which is a common and low-risk corporate event.
Key Numbers
- DKK 1.1 million — Capital Increase (Resulting from employee warrant exercise on September 9, 2025.)
- USD 0.16 million — Capital Increase (USD) (Equivalent amount in US dollars.)
Key Players & Entities
- Genmab A/S (company) — Registrant
- September 9, 2025 (date) — Filing date and announcement date
- DKK 1.1 million (dollar_amount) — Capital increase amount
- USD 0.16 million (dollar_amount) — Capital increase amount in USD
- Form 6-K (document) — Filing type
FAQ
What is the primary purpose of this Form 6-K filing?
This Form 6-K is filed to report a company announcement dated September 9, 2025, regarding a capital increase in Genmab A/S as a result of employee warrant exercise.
What was the approximate amount of the capital increase?
The capital increase was approximately DKK 1.1 million (USD 0.16 million).
When did this capital increase occur?
The capital increase occurred as a result of employee warrant exercise, as announced on September 9, 2025.
What type of securities were exercised by employees?
Employees exercised warrants, leading to the capital increase.
Is this filing considered part of Genmab's registration statements?
Yes, this report on Form 6-K is deemed to be incorporated by reference into Genmab A/S's registration statements on Form S-8.
Filing Stats: 250 words · 1 min read · ~1 pages · Grade level 15.2 · Accepted 2025-09-09 15:02:33
Filing Documents
- gmab_20250909x6k.htm (6-K) — 14KB
- gmab_20250909xxex99d1.htm (EX-99.1) — 22KB
- gmab_20250909xxex99d2.htm (EX-99.2) — 36KB
- genmab_logoa.jpg (GRAPHIC) — 56KB
- genmab_logob.jpg (GRAPHIC) — 56KB
- 0001434265-25-000074.txt ( ) — 221KB
From the Filing
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF SEPTEMBER 2025 COMMISSION FILE NUMBER 001-38976 Genmab AS (Exact name of Registrant as specified in its charter) Carl Jacobsens Vej 30 2500 Valby Denmark +45 70 20 27 28 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F Form 40-F This report on Form 6-K shall be deemed to be incorporated by reference in Genmab AS's registration statements on Form S-8 (File No. 333-232693, 333-253519, 333-262970, 333-277273 and 333-284876 ) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished. EXHIBIT INDEX Exhibit Description of Exhibit 99.1 Company Announcement Dated September 9, 2025 Capital Increase in Genmab as a Result of Employee Warrant Exercise 99.2 Company Announcement Dated September 9, 2025 Transactions with shares and linked securities in Genmab AS made by managerial employees and their closely associated persons SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. GENMAB AS BY s Anthony Pagano Name Anthony Pagano Title Executive Vice President Chief Financial Officer DATE SEPTEMBER 9, 2025